Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roll-On Buy Biel Today
OWN SNAP Bioelectronics (BIEL) Moves Up On High Volume: Now What?
February 1, 2021 By Michael Rowels
If you are looking to get into stocks that have been displaying considerable momentum then it might be a good idea to track the Bioelectronics Corp (OTC: BIEL) stock.
The stock has displayed strong momentum in recent days and over the course of the last week, it managed to deliver gains of as much as 50%. The trigger for the rally in BioElectronics might have been the announcement of the company’s fourth-quarter results back on January 19.
BioElectronics managed to generate revenues of $519,000 in the quarter, which represents a massive jump of as high as 241% from the previous quarter.
The revenues stood at $152,000 in the third quarter. However, more importantly, the company announced that on top of the revenues it generated, there are going to be deferred revenues to the tune of $554,000. Lastly, the two biggest lenders to BioElectronics have also decided to forego interest payments totaling as much as $750,000 in 2020 and are going to do the same in 2021.
Michael Rowels
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.
https://ownsnap.com/page/2/
DING DING They Already Have ReStocked LMAO
Been using ETrade since 2006 to buy Biel
We have added partners in Sweden, Romania and Italy this week. Orders in hand. Further validation of global demand. RRX continues to surpass our goals for a successful launch. #AllAboard #goteam
@BielCorp
#topofthefirst
10:31 AM · Jan 29, 2021
Keith Nalepka
@keith_nalepka
Biel might need more warehouse space, soon.
.0002 was my lowest
CDC provisional data from 2019 show that 31.7% of all births were by c-section. Drug-free, US FDA cleared
@RecoveryRx for post-surgical pain allows for safer breastfeeding. #innovation #drugfree #postsurgical #painrelief #cesarean #breastfeeding #clinicallyproven #obstetrics
BioElectronics Corp
@BielCorp
Historic amazing day for @BielCorp
execution of a great plan. This is what stocking/backfilling national retailers look like. Proud of the team. #brickbybrick #salestrac #allaboard
Historic amazing day for
Keith Nalepka
@keith_nalepka
Historic amazing day for @BielCorp execution of a great plan. This is what stocking/backfilling national retailers looks like. Proud of the team. #brickbybrick #salestrac #allaboard pic.twitter.com/LBJpITqgb0
— Keith Nalepka (@keith_nalepka) January 28, 2021
Let the good times roll on go Biel and Jimbo supplying the Yam=Yam juice. Kelly and team kicking ass, Big thanks.
LMFAO Sure
LMAO What A Load Of Pig Crap In The Post Related To Biel
We have FDA clearance nothing else needed surely not pig crap, I wonder what the difference between Tens and Actipatch LOL
BioElectronics Corporation Announces Substantial Increase in 4th Quarter 2020 Revenue; Major Convertible Debt Holders Agree to Forego Interest in 2021
BIEL
+23.33%
Release #:812-197420-rl-1141231:
Frederick, Maryland, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (OTC PINK:BIEL) is pleased to report that Q4 revenue for 2020 exceeded $519,000, representing an increase of 241% when compared to Q3 revenue in 2020 ($151,956). Correspondingly, Q4 2020 revenue represents an increase of 233% when compared to the cumulative revenue of Q1 and Q2 in 2020 ($155,818).
As of today, the Company has $554,074 in deferred revenue remaining on the books, at least half of which is scheduled to ship in Q1 of 2021.
Richard Staelin, Ph.D., Chairman of the Board, said, “We believe this increase in both revenue and deferred revenue is a strong signal that the firm is moving in the right direction.” He attributes this robust growth to the firm’s unique portfolio of products and the management’s decision to prioritize partnerships with entities that have a strong brand recognition and significant retail presence.
Keith Nalepka, VP of Sales, commented: “We are pleased with the increase in revenue and look forward to the national retail rollout of KT Recovery+Wave™ and the DonJoy® Advantage products, Powered by ActiPatch®. We are simultaneously bringing on more international distribution channels and ramping up our efforts to market and sell the RecoveryRx® brand domestically.”
The managers of the firm’s two largest lenders, which are both controlled by Whelan family members, Ibex LLC and St. John’s LLC, have agreed to extend foregoing of interest due on their convertible debt notes through the end of 2021. Kelly Whelan, President & CEO of BioElectronics, stated: “It is the goal of both BioElectronics’ management team and the Whelan family to bring the Company to profitability as swiftly as possible, for the benefit of all shareholders. The Whelan family has collectively foregone interest in excess of $750,000 in 2020, and will extend this hiatus on interest collection through at least 2021.”
Dr. Staelin noted that “the Board is deeply appreciative of the Whelan family foregoing any interest in 2020 and 2021. This decrease in interest expenses coupled with a steady increase in sales will bring the firm much closer to its goal of posting profits in the near future.”
About BioElectronics Corporation
Headquartered in Frederick, Maryland, and founded in 2000, BioElectronics Corporation is the leading company in the field on non-invasive electroceutical medical devices. BioElectronics is the maker of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Therapy for postoperative pain and chronic wound care.
FORWARD LOOKING STATEMENTS
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
Post Related To ActiPatch is worthless placebic junk.
LMAO WHAT A JOKE
OFF The Wall crap in the post related to Biel
LMAO $77.8 Billion Small Niche GEEZ
Post related to Biel is the biggest JOKE EVER
Oh Well sometimes it's really hard to see the trees go Biel
Read it again not talking about sports use
Greg Venner, CEO of KT Health, commented, “We are extremely pleased to be partnering with BioElectronics on such an innovative and effective product. KT Recovery+ Wave™ allows KT Health to broaden our drug-free pain relief options, expanding our product line into the chronic pain category. We look forward to a long and productive partnership with BioElectronics.”
NOW READ IT AGAIN Key Words Like "ExPANDING"
Greg Venner, CEO of KT Health, commented, “We are extremely pleased to be partnering with BioElectronics on such an innovative and effective product. KT Recovery+ Wave™ allows KT Health to broaden our drug-free pain relief options, expanding our product line into the chronic pain category. We look forward to a long and productive partnership with BioElectronics.”
NOW READ IT AGAIN Key Words Like "ExPANDING"
Innovations in Field of Pain Management Are Major Market Trend
The key trend being observed in the chronic pain treatment market is the rapid innovations in this field. One of the key advancements in this sector is the advent of the wearable technology for the treatment of chronic pain in old, as well as young patients. This technology is proving to be of great help for working people suffering from chronic illnesses. Moreover, several companies are focusing on the development of non-opioid pain therapies. Further, portable devices for chronic pain treatment have provided greater comfort to older patients. Therefore, the increasing number of innovations in pain management products and devices are fueling the growth of the industry.
https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market#:~:text=Chronic%20Pain%20Treatment%20Market%20Overview,period%20(2020%E2%80%932030).
LMAO REALLY-The-global-chronic-pain-treatment-market-valued-$77.8-billion in 2019, and it is expected to grow at a 6.5% CAGR during the forecast period (2020–2030).
fiyah Urban Dictionary defines A variation of the word fire. Fiyah is slang describing anything that is hot or dope (good). Yep Biel is really good
LMAO Just More Nonsense BS In Post Related To Biel
LMAO POST MUST BE A JOKE RELATED TO BIEL
LMAO An Opinion Related To Biel That Means Nothing With No Facts Just BS
The Post Related To Biel is a scam.
Keith Nalepka-Starting-the-year-strong-great-sales-rebound in 4th qtr, multiple national chains being stocked as we speak, follow on orders received early, RRX is rolling, UK back, Mexico added,
@BielCorp
#takeoff #brickbybrick #team
@keith_nalepka·2h
Chronic Pain Treatment Market to Reach $105.9 Billion by 2024: P&S Intelligence
https://www.globenewswire.com/news-release/2019/01/07/1680944/0/en/Chronic-Pain-Treatment-Market-to-Reach-105-9-Billion-by-2024-P-S-Intelligence.html
Greg Venner, CEO of KT Health, commented, “We are extremely pleased to be partnering with BioElectronics on such an innovative and effective product. KT Recovery+ Wave™ allows KT Health to broaden our drug-free pain relief options, expanding our product line into the chronic pain category. We look forward to a long and productive partnership with BioElectronics.” Amazing how big the chronic back pain market is by itself. I think the CEO Of KT Health is focused on the Chronic Pain Market BIG $$$$$$$$$$$$$$
https://blog.marketresearch.com/lower-back-pain-market-trends
LMAO I'm Suppose To Make An Investment Decision On The Post
ACTIPATCH-RecoveryRX the most interesting device in the whole world for chronic pain DRUG-FREE.
Saved Your foot from frostbite per you
LMAO Nothing But False Post Related To RecoveryRX
LMAO False misinformation being posted related to Biel is not going to change the direction of Biel
LMAO pure Pig Crap in the post related to Biel
POST-Full Of Pig Crap Related To Biel
KT Recovery+Wave Is WATERPROOF
Establishment Registration & Device Listing
FDA Medical Devices Databases
Proprietary Name: KT Recovery+ Wave
Classification Name: NONTHERMAL SHORTWAVE THERAPY DEVICE INDICATED FOR OVER THE COUNTER USE FOR THE TREATMENT OF PAIN
Product Code: PQY
Device Class: 2
Regulation Number: 890.5290
Medical Specialty: Physical Medicine
Registered Establishment Name: KT Health, LLC
Registered Establishment Number: 3007282994
Premarket Submission Number: K192234
Owner/Operator: KT Health LLC
Owner/Operator Number: 10027415
Establishment Operations: Repackager/Relabeler
-
-
Page